Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Tomoko Kirihara"'
Autor:
Kota Sato, Naoko Takada, Amane Fujioka, Noriko Himori, Yu Yokoyama, Satoru Tsuda, Kazuko Omodaka, Tomoko Kirihara, Makoto Ishikawa, Hiroshi Kunikata, Toru Nakazawa
Publikováno v:
Journal of Glaucoma; Sep2023, Vol. 32 Issue 9, p734-747, 4p
Autor:
Noriko Odani-Kawabata, Ryo Iwamura, Takazumi Taniguchi, Tomoko Kirihara, Atsushi Shimazaki, Masahiro Fuwa, Kenji Morishima, Kenji Yoneda, Naveed Shams, Masatomo Kato
Publikováno v:
Journal of Ocular Pharmacology and Therapeutics. 37:223-229
Purpose: To investigate the intraocular pressure (IOP)-lowering effects of omidenepag isopropyl (OMDI), a potent and highly selective prostanoid EP2 receptor agonist, as a potential first-line ocul...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a06ce19eed1bf26589d524e14b80da21
https://doi.org/10.1089/jop.2020.0071
https://doi.org/10.1089/jop.2020.0071
Autor:
Masahiro Fuwa, Kenji Ueda, Takahiro Akaishi, Naoko Yamashita, Tomoko Kirihara, Atsushi Shimazaki, Hidetoshi Mano, Kouichi Kawazu
Publikováno v:
PLoS ONE, Vol 11, Iss 7, p e0158797 (2016)
To compare the safety and efficacy of fixed-dose tafluprost/timolol combination (Taf/T-FDC) with those of fixed-dose latanoprost/timolol combination (Lat/T-FDC) by measuring the intraocular pressure (IOP)-lowering effect, ocular pharmacokinetics, and
Externí odkaz:
https://doaj.org/article/534232eb8ca54e9883de491486d5ecfd
A Novel Non‐Prostaglandin EP2‐Receptor Agonist for Glaucoma Treatment: Omidenepag Isopropyl (DE‐117)
Autor:
Ryo Iwamura, Tomoko Kirihara, Helen Lu, Noriko Odani-Kawabata, Kenji Yoneda, Sharif Najam A, Naveed Shams
Publikováno v:
The FASEB Journal. 34:1-1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::49f5a9fbf034674d53f84461907be240
https://doi.org/10.1096/fasebj.2020.34.s1.08817
https://doi.org/10.1096/fasebj.2020.34.s1.08817
Autor:
Eiji Okanari, Tomoko Kirihara, Kenji Yoneda, Ryo Iwamura, Naveed K Shams, Noriko Odani-Kawabata, Masayuki Tanaka
Publikováno v:
Journal of medicinal chemistry. 61(15)
EP2 receptor agonists are expected to be effective ocular hypotensive agents; however, it has been suggested that agonism to other EP receptor subtypes may lead to undesirable effects. Through medicinal chemistry efforts, we identified a scaffold bea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00f458e261a47f1077ac8e3431a66d45
https://pubmed.ncbi.nlm.nih.gov/29995405
https://pubmed.ncbi.nlm.nih.gov/29995405
Autor:
Atsushi Shimazaki, Masahiro Fuwa, Takahiro Akaishi, Naoko Yamashita, Hidetoshi Mano, Tomoko Kirihara, Kenji Ueda, Kouichi Kawazu
Publikováno v:
PLoS ONE
PLoS ONE, Vol 11, Iss 7, p e0158797 (2016)
PLoS ONE, Vol 11, Iss 7, p e0158797 (2016)
Purpose To compare the safety and efficacy of fixed-dose tafluprost/timolol combination (Taf/T-FDC) with those of fixed-dose latanoprost/timolol combination (Lat/T-FDC) by measuring the intraocular pressure (IOP)-lowering effect, ocular pharmacokinet
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79bea3d8630d999db0658a16582e6fb5
https://pubmed.ncbi.nlm.nih.gov/27383260
https://pubmed.ncbi.nlm.nih.gov/27383260
Autor:
Takazumi Taniguchi, Noriko Odani-Kawabata, Tomoko Kirihara, Atsushi Shimazaki, Kenzo Yamamura, Kenji Yoneda, Takeshi Matsugi, Jin-Zhong Zhang, Naveed K Shams, Ryo Iwamura
Publikováno v:
Investigative Opthalmology & Visual Science. 59:145
Purpose The objective of this study was to investigate the pharmacologic characteristics of omidenepag isopropyl (OMDI), a compound developed as a novel intraocular pressure (IOP)-lowering agent, with better IOP control and fewer side effects than ot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5b73ea39ab3a1504a8f4aeb4389c141
https://doi.org/10.1167/iovs.17-22745
https://doi.org/10.1167/iovs.17-22745
Autor:
Yuko Yoshinobu, Yoichi Minami, Shigenobu Shibata, Masashi Akiyama, Takahiro Moriya, Satomi Takahashi, Tomoko Kirihara
Publikováno v:
British Journal of Pharmacology. 128:1616-1622
1. The mPer1 and mPer2 genes are putative mouse clock genes that regulate circadian oscillator present in the suprachiasmatic nucleus (SCN) neuron. While they are also expressed in the granular cell layer in the cerebellum, their function is unknown.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64f34ccf9581ac0aa9a48bd5f3ad4ff0
https://doi.org/10.1038/sj.bjp.0702957
https://doi.org/10.1038/sj.bjp.0702957
Publikováno v:
Experimental eye research. 119
We investigated the effects of Src-family tyrosine kinase (SFK) inhibitors on intraocular pressure (IOP) and trabecular meshwork (TM) cells. The SFK inhibitors, PP2, PP1, and damnacanthal, significantly lowered IOP from baseline following intracamera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::378723a7356d6e019885b42f6140a75d
https://pubmed.ncbi.nlm.nih.gov/24321889
https://pubmed.ncbi.nlm.nih.gov/24321889
Autor:
Takeshi Matsugi, Atsushi Shimazaki, Hisashi Tajima, Tomoko Kirihara, David L. Epstein, Ponugoti Vasantha Rao
Publikováno v:
Biologicalpharmaceutical bulletin. 30(8)
To evaluate the pharmacological characteristics of SA12590, a new oxime-derivative of the ethacrynic acid (ECA) derivative SA9000, we examined both its ocular hypotensive effects (in ocular normotensive cats and cynomolgus monkeys) and its potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38187932c27764a57be98877bc61ef1c
https://pubmed.ncbi.nlm.nih.gov/17666801
https://pubmed.ncbi.nlm.nih.gov/17666801